title: Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial.
abstract: OBJECTIVE
  To evaluate the effect of adjunctive intraocular triamcinolone acetonide (TA) in silicone-filled eyes on outcomes of vitreoretinal surgery for proliferative vitreoretinopathy (PVR).
  
  
  METHODS
  Prospective, randomized, controlled clinical trial.
  
  
  METHODS
  Seventy-five eyes with rhegmatogenous retinal detachment and PVR grade C (posterior, anterior, or both) undergoing vitrectomy combined with silicone oil tamponade were included. Of these, 38 eyes were assigned randomly to the adjunctive treatment, whereas 37 eyes served as controls.
  
  
  METHODS
  All eyes underwent pars plana vitrectomy, membrane peeling, and silicone oil exchange, with or without relaxing retinotomy or retinectomy. In the treatment group, 4 mg TA was injected into the silicone-filled vitreous cavity at the end of the procedure. Silicone oil was removed 3 months after surgery in eyes with attached retinas.
  
  
  METHODS
  The primary outcome measure was retinal reattachment rate at 6 months. Secondary outcome measures included visual acuity, rate of recurrent PVR, reoperation rate, and rise of intraocular pressure.
  
  
  RESULTS
  Retinal reattachment without any reoperation was achieved in 32 eyes (84.2%) and 29 eyes (78.4%) in the adjunctive treatment and control groups, respectively, at 6 months (P = 0.5). No statistically significant difference was observed between the 2 groups in terms of any of the secondary outcome measures (P>0.05).
  
  
  CONCLUSIONS
  The outcomes of vitreoretinal surgery for established PVR are not improved significantly by adjunctive TA injection in silicone-filled eyes.
authors.affiliation: Ophthalmic Research Center, Labbafinejad Medical Center, Shahid Beheshti University, M.C., Tehran, Iran.
authors.forename: Hamid
authors.initials: H
authors.lastname: Ahmadieh
authors.forename: Mostafa
authors.initials: M
authors.lastname: Feghhi
authors.forename: Homa
authors.initials: H
authors.lastname: Tabatabaei
authors.forename: Nasser
authors.initials: N
authors.lastname: Shoeibi
authors.forename: Alireza
authors.initials: A
authors.lastname: Ramezani
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Mohebbi
mesh_terms: D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007267:Injections; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012163:Retinal Detachment / Q000601:surgery*; D012827:Silicone Oils / Q000008:administration & dosage*; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014821:Vitrectomy; D018630:Vitreoretinopathy, Proliferative / Q000188:drug therapy* / Q000601:surgery*; D014822:Vitreous Body
chemical_list: D007166:Immunosuppressive Agents; D012827:Silicone Oils; D014222:Triamcinolone Acetonide